CytRx, a biopharmaceutical research and development company specializing in oncology treatments, reported today it will be at the Oppenheimer 24th annual Healthcare Conference, being held next week in New York City. The conference is being held Tuesday, December 10 through Wednesday, December 11, 2013, at the Crowne Plaza Hotel. The company's President and CEO, Steven A. Kriegsman, and Executive Vice President and Chief Medical Officer, Dr. Daniel Levitt, will be providing a corporate update on Wednesday, December 11, 2013 at 4:30 PM EST.
The presentation will be webcast, available at: www.cytrx.com/investors/presentations
The Oppenheimer conference is an event in which management teams from over 100 companies present up-to-date information on their companies and their performances. Presenters cover a wide range of public and private healthcare companies spanning over all of the healthcare industry, including: bio & specialty pharmaceuticals; biotechnology; medical devices; healthcare facilities; life science tools and diagnostics; healthcare information technology and distribution, and healthcare providers and servicers.
CytRx's oncology pipeline is currently focused on the clinical development of aldoxorubicin, its improved version of the widely-used chemotherapeutic treatment doxorubicin.
Information about CytRx's Aldoxorubicin Clinical Trial Progress
CytRx is conducting a global Phase 2b clinical trial with aldoxorubicin as a treatment for soft tissue sarcomas, has completed its Phase 1b/2 clinical trial primarily in the same indication and a Phase 1b study of aldoxorubicin in combination with doxorubicin in patients with advanced solid tumors, and has completed a Phase 1b pharmacokinetics clinical trial in patients with metastatic solid tumors. CytRx plans to initiate under a special protocol assessment a potential pivotal Phase 3 global trial with aldoxorubicin as a therapy for patients with soft tissue sarcomas whose tumors have progressed following treatment with chemotherapy. CytRx also has initiated a Phase 2 clinical trial with aldoxorubicin in patients with late-stage glioblastoma (brain cancer) and plans to initiate a Phase 2 clinical trial for AIDS-related Kaposi's sarcoma.
In an article on StreetInsider.com, analyst Ram Selvaraju noted CytRx's positive indicators as a stock buy, saying, "Over the course of the past several weeks, CytRx has reported several significant developments. The firm previously reported positive response data from a Phase 2b trial assessing aldoxorubicin versus doxorubicin as front-line therapy in soft tissue sarcoma (NYSEMKT:STS)."
The full article can be accessed at: www.streetinsider.com/Analyst+Comments/P....html
For more information on CytRx, visit: cytrx.com
MissionIR provides investor relations services to publicly traded companies in exchange for compensation. This article may be part of our efforts to widen a client's exposure. To read our full disclaimer, visit http://disclaimer.missionir.com